Genentech Inks Licensing Deal With Jemincare Over Androgen Receptor Degrader

Roche subsidiary Genentech has inked a licensing deal with China-based Jemincare, gaining worldwide rights to develop and commercialize the company’s investigational androgen receptor degrader JMKX002992.

The companies believe the oral drug candidate has the potential to treat patients with prostate cancer who have developed resistance to current therapies.

In prostate cancer patients, androgens bind to androgen receptors inside the cancer cells, causing the cancer cells to grow.

Genentech will pay a $60 million upfront payment to Jemincare, with potential additional milestone payments of up to $950 million.